{"entity":{"id":"nct07798947","kind":"trial","name":"A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC","aka":[],"tldr":"A phase 2 trial of adebrelimab in lung cancer, run by Shanghai Hengrui Pharmaceutical Co., Ltd., not yet recruiting.","summary":"A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC is a phase 2, interventional study registered as NCT07798947 by Shanghai Hengrui Pharmaceutical Co., Ltd., with a registry enrolment figure of 120 participants, started 2026-09 and due to reach its primary completion in 2028-12. Interventions recorded: SHR-7787 Injection; SHR-1316. Conditions listed: Limited-stage Small-cell Lung Cancer. Primary outcome: Incidence and severity of adverse events (AEs); Incidence and severity of serious adverse events (SAEs); Progression-Free Survival (PFS). Lung eligibility wording from the registry: \"Histologically or cytologically confirmed unresectable limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemotherapy and radiation therapy\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07798947","url":"https://clinicaltrials.gov/study/NCT07798947"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["limited-stage-sclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["adebrelimab"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07798947","phase":"2","setting":"A Multicenter, Open-label, Phase II Clinical Study of SHR-7787 Injection Combined With Adebrelimab in Patients With Limited Stage Small Cell Lung Cancer","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","enrolled":120,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07798947/","neighbours":{"cancer":[{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}